Mobile

A 14-Month Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 as an Adjunctive Therapy in Patients With Refractory Partial Seizures (rev...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-004293-24

A 14-Month Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 as an Adjunctive Therapy in Patients With Refractory Partial Seizures (revised per Amendments 02 and 03)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective for this study is to evaluate the safety of E2007 given as adjunctive, long-term treatment in patients with refractory partial onset seizures with or without secondary generalization that completed the E2007-A001-206 or the E2007-G000-208 study.

Critère d'inclusion

  • E2007 is given as adjunctive, long-term treatment in patients with refractory partial onset seizures with or without secondary generalization

Liens